Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156348037> ?p ?o ?g. }
- W2156348037 endingPage "678" @default.
- W2156348037 startingPage "672" @default.
- W2156348037 abstract "Myeloproliferative neoplasms are a varied group of disorders that can have prolonged chronic phases, but eventually accelerate and can transform into a secondary acute myeloid leukemia that is ultimately fatal. Triapine is a novel inhibitor of the M2 subunit of ribonucleotide reductase. Sequential inhibition of ribonucleotide reductase with triapine and an M1 ribonucleotide reductase inhibitor (fludarabine) was noted to be safe, and led to a 29% complete plus partial response rate in myeloproliferative neoplasms. This article reports the findings of a phase II trial of triapine (105 mg/m(2)/day) followed by fludarabine (30 mg/m(2)/day) daily for 5 consecutive days in 37 patients with accelerated myeloproliferative neoplasms and secondary acute myeloid leukemia. The overall response rate was 49% (18/37), with a complete remission rate of 24% (9/37). Overall response rates and complete remissions were seen in all disease subsets, including secondary acute myeloid leukemia, in which the overall response rate and complete remission rate were 48% and 33%, respectively. All patients with known JAK2 V617F mutations (6/6) responded. The median overall survival of the entire cohort was 6.9 months, with a median overall survival of both overall responders and complete responders of 10.6 months. These data further demonstrate the promise of sequential inhibition of ribonucleotide reductase in patients with accelerated myeloproliferative neoplasms and secondary acute myeloid leukemia. This study was registered with clinicaltrials.gov (NCT00381550)." @default.
- W2156348037 created "2016-06-24" @default.
- W2156348037 creator A5012591920 @default.
- W2156348037 creator A5016810759 @default.
- W2156348037 creator A5040303721 @default.
- W2156348037 creator A5040758762 @default.
- W2156348037 creator A5045709974 @default.
- W2156348037 creator A5046719320 @default.
- W2156348037 creator A5052920087 @default.
- W2156348037 creator A5059680271 @default.
- W2156348037 creator A5074468239 @default.
- W2156348037 creator A5078527108 @default.
- W2156348037 creator A5079274832 @default.
- W2156348037 creator A5080736692 @default.
- W2156348037 date "2013-12-20" @default.
- W2156348037 modified "2023-10-12" @default.
- W2156348037 title "A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms" @default.
- W2156348037 cites W1171060 @default.
- W2156348037 cites W138942642 @default.
- W2156348037 cites W1535189264 @default.
- W2156348037 cites W1541537086 @default.
- W2156348037 cites W1575991619 @default.
- W2156348037 cites W1819781110 @default.
- W2156348037 cites W1857665725 @default.
- W2156348037 cites W1905059524 @default.
- W2156348037 cites W1925684361 @default.
- W2156348037 cites W1963418965 @default.
- W2156348037 cites W1974602590 @default.
- W2156348037 cites W1985759147 @default.
- W2156348037 cites W1996502308 @default.
- W2156348037 cites W1996745005 @default.
- W2156348037 cites W1996934902 @default.
- W2156348037 cites W2009114635 @default.
- W2156348037 cites W2015576599 @default.
- W2156348037 cites W2022237067 @default.
- W2156348037 cites W2025399633 @default.
- W2156348037 cites W2029529782 @default.
- W2156348037 cites W2042453360 @default.
- W2156348037 cites W2045969716 @default.
- W2156348037 cites W2046719918 @default.
- W2156348037 cites W2049965335 @default.
- W2156348037 cites W2056116861 @default.
- W2156348037 cites W2060150207 @default.
- W2156348037 cites W2083482286 @default.
- W2156348037 cites W2084590133 @default.
- W2156348037 cites W2085972813 @default.
- W2156348037 cites W2096638244 @default.
- W2156348037 cites W2098068347 @default.
- W2156348037 cites W2100417543 @default.
- W2156348037 cites W2120079339 @default.
- W2156348037 cites W2121743767 @default.
- W2156348037 cites W2123633897 @default.
- W2156348037 cites W2129510594 @default.
- W2156348037 cites W2130041404 @default.
- W2156348037 cites W2133283496 @default.
- W2156348037 cites W2300371971 @default.
- W2156348037 cites W2320032845 @default.
- W2156348037 cites W2413781613 @default.
- W2156348037 cites W2582743722 @default.
- W2156348037 cites W61375579 @default.
- W2156348037 cites W1697067943 @default.
- W2156348037 cites W2147083172 @default.
- W2156348037 doi "https://doi.org/10.3324/haematol.2013.097246" @default.
- W2156348037 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3971077" @default.
- W2156348037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24362550" @default.
- W2156348037 hasPublicationYear "2013" @default.
- W2156348037 type Work @default.
- W2156348037 sameAs 2156348037 @default.
- W2156348037 citedByCount "48" @default.
- W2156348037 countsByYear W21563480372014 @default.
- W2156348037 countsByYear W21563480372015 @default.
- W2156348037 countsByYear W21563480372016 @default.
- W2156348037 countsByYear W21563480372017 @default.
- W2156348037 countsByYear W21563480372018 @default.
- W2156348037 countsByYear W21563480372019 @default.
- W2156348037 countsByYear W21563480372020 @default.
- W2156348037 countsByYear W21563480372021 @default.
- W2156348037 countsByYear W21563480372022 @default.
- W2156348037 countsByYear W21563480372023 @default.
- W2156348037 crossrefType "journal-article" @default.
- W2156348037 hasAuthorship W2156348037A5012591920 @default.
- W2156348037 hasAuthorship W2156348037A5016810759 @default.
- W2156348037 hasAuthorship W2156348037A5040303721 @default.
- W2156348037 hasAuthorship W2156348037A5040758762 @default.
- W2156348037 hasAuthorship W2156348037A5045709974 @default.
- W2156348037 hasAuthorship W2156348037A5046719320 @default.
- W2156348037 hasAuthorship W2156348037A5052920087 @default.
- W2156348037 hasAuthorship W2156348037A5059680271 @default.
- W2156348037 hasAuthorship W2156348037A5074468239 @default.
- W2156348037 hasAuthorship W2156348037A5078527108 @default.
- W2156348037 hasAuthorship W2156348037A5079274832 @default.
- W2156348037 hasAuthorship W2156348037A5080736692 @default.
- W2156348037 hasBestOaLocation W21563480371 @default.
- W2156348037 hasConcept C104292427 @default.
- W2156348037 hasConcept C104317684 @default.
- W2156348037 hasConcept C126322002 @default.
- W2156348037 hasConcept C2776694085 @default.
- W2156348037 hasConcept C2776755627 @default.